Trials / Terminated
TerminatedNCT02129400
Influence on Erythropoetin-level by Xenon
Xenon-inhalation: Elimination of Xenon and Its Effect on Erythropoetin Levels in Blood of Healthy Volunteers
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- RWTH Aachen University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to analyze the effect of xenon-inhalation on erythropoetin-level in blood of healthy volunteers and to determine the efficient time of inhalation. Hypothesis: Xenon-inhalation enhances erythropoetin-levels in blood
Detailed description
Xenon-gas is an approved anesthetic by the EMEA and is used for a balanced anesthesia in combination with opioids for adults with a american society of anesthesiology classification ASA ≤ III. Several clinical and pre-clinical studies have shown a positive effect of xenon on several organ functions such as in brain, kidneys and heart. In two studies, an enhanced expression of hypoxia inducible factor-1α (HIF-1α) could be shown in animal kidneys and kidney cells. Interestingly, HIF-1α leads to an enhanced formation of erythropoetin (EPO). This might result in an enhanced oxygen transport capacity and an enhanced oxygen-level after xenon-treatment. Aim of the project is to analyze the effect of xenon-inhalation on circulating erythropoetin-level in blood of healthy volunteers in a randomized controlled pilot study. Besides, other positive stimulating factors for erythropoiesis (such as HIFa stabilizing factors) and growth factors (such as fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), mechano growth factors (MGFs), platelet-derived growth factors (PDGFs), vascular endothelial growth factors (VEGFs)) shall be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xenon pro Anaesthesia 100 % (V/V) | Xenon-gas inhalation of indicated concentrations during indicated time |
| DRUG | Aer medicinalis Linde 100% |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2014-05-02
- Last updated
- 2015-03-31
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02129400. Inclusion in this directory is not an endorsement.